Supplementary Information for

ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma

Natasha D. Sheybani[1], Victoria R. Breza [1], Soumen Paul[2], Katelyenn S. McCauley[2], Stuart S. Berr[2], G. Wilson Miller[1,2], Kiel D. Neumann[2], Richard J. Price[1,2]

Corresponding Authors: Richard J. Price and Natasha D. Sheybani

E-mail: rprice@virginia.edu; nds3sa@virginia.edu



Figure S1. Representative longitudinal Immuno-PET images. Axial decay-corrected fused PET/CT (left) and SUV (right) images for representative mice in each experimental group on D14-15 (A) and D16 (B). Zoomed insets (white box) in the targeted hemisphere depict qualitative differences in [^{89}Zr]-mCD47 uptake across FUS groups. Scale unit: % Injected Dose (ID) per mL. Note that images could not be shown on the same scale across all timepoints due to signal saturation in select groups.



Figure S2. Overall survival of control GL261-bearing mice. Kaplan-Meier curve depicting overall survival of control GL261-bearing mice receiving systemic control IgG antibody. Treatments were initiated either 8 (D8) or 14 (D14) days post-implantation. *n*=5 mice per group. Significance assessed by log-rank (Mantel-Cox) test. No significant difference detected.



Figure S3. BBB/BTB permeability in baseline pre-treatment planning MRIs from mCD47 survival study. (A, B) Representative baseline contrast-enhanced MR images of GL261 tumor-bearing brains at Day 17. (C) Mean greyscale intensity (MGI) of contrast enhancement for GL261 tumors in mCD47 and mCD47+FUS groups, calculated as fold change over contralateral brain. *p=0.0093. Significance assessed by RM mixed effects model implementing restricted maximum likelihood method, followed by Sidak's multiple comparison correction.